[1]王在川,华 琳.SOD基因多态性与COPD易感性的Meta分析[J].医学信息,2018,(17):57-62.[doi:10.3969/j.issn.1006-1959.2018.17.018]
 WANG Zai-chuan,HUA Lin.Meta-analysis of SOD Gene Polymorphism and Susceptibility to COPD[J].Medical Information,2018,(17):57-62.[doi:10.3969/j.issn.1006-1959.2018.17.018]
点击复制

SOD基因多态性与COPD易感性的Meta分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年17期
页码:
57-62
栏目:
论著
出版日期:
2018-09-01

文章信息/Info

Title:
Meta-analysis of SOD Gene Polymorphism and Susceptibility to COPD
文章编号:
1006-1959(2018)17-0057-06
作者:
王在川1华 琳2
1.首都医科大学2016级长学制临床医学专业,北京 100069; 2.首都医科大学生物医学工程学院,北京 100069
Author(s):
WANG Zai-chuan1HUA Lin2
1.Grade 2016 Long Term System,Clinical Medicine Major,Capital Medical University,Beijing 100069,China; 2.College of Biomedical Engineering,Capital Medical University,Beijing 100069,China
关键词:
超氧化物歧化酶慢性阻塞性肺疾病基因多态性Meta分析
Keywords:
Key words:Superoxide dismutaseChronic obstructive pulmonary diseaseGene polymorphismMeta-analysis
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2018.17.018
文献标志码:
A
摘要:
目的 系统评价SOD中SOD1 +35A/C,SOD2 Val 16 Ala,SOD3 R213G基因多态性与慢性阻塞性肺疾病的相关性。方法 检索CBM、CNKI、万方、VIP、EmBase和PubMed等中英文数据库,收集上述基因多态性与COPD的关系。采用Stata 12.0软件进行统计分析,以病例组和对照组基因型分布比值比及其95%可信区间(95%CI)表示其关联强度。结果 共纳入研究11项,其中病例组5915例,对照组96831例。Meta分析结果显示,SOD1 +35A/C(CA vsAA:OR:1.31;95%CI:0.88~1.95)、SOD2 Val 16 Ala (TC vsTT: OR:1.31;95%CI:0.88~1.95;CC vsTT:OR:0.93;95%CI:0.68~1.28)、SOD3 R213G (CA vsAA:OR,0.98;95%CI:0.63~1.53)基因多态性可能与COPD易感性无关,SOD3 R213G相关研究异质性较大(I2=68.8%),分组分析结果显示异质性主要来自于吸烟人群中。结论 SOD1 +35A/C,SOD2 Val 16 Ala,SOD3 R213G基因多态性可能与COPD易感性无关,但在吸烟人群中SOD3 R213G多态性对COPD的影响需更多大样本的研究进一步证实。
Abstract:
Abstract:Objective To assess the SOD SOD1+35A/C,SOD2 Val 16 Ala,SOD3 R213G polymorphisms and chronic obstructive pulmonary disease relevance.Methods Chinese and English databases such as CBM,CNKI,Wanfang,VIP,EmBase and PubMed were searched to collect the relationship between the above gene polymorphisms and COPD.Statistical analysis was performed using Stata 12.0 software,and the correlation strength between the case group and the control group genotype distribution ratio and its 95% confidence interval(95%CI).Results A total of 11 studies were included,of which 5915 were in the case group and 96831 in the control group.Meta-analysis results showed that SOD1+35A/C(CA vsAA:OR:1.31;95%CI:0.88~1.95),SOD2 Val 16 Ala(TC vsTT:OR: 1.31;95%CI:0.88~1.95;CC vsTT:OR:0.93;95%CI:0.68~1.28),the polymorphism of SOD3 R213G(CA vsAA:OR,0.98;95%CI:0.63~1.53)may not be related to the susceptibility to COPD,and the heterogeneity of SOD3 R213G correlation study is large(I2=68.8%).The results of the group analysis showed that the heterogeneity mainly came from the smoking population.Conclusion The SOD1 +35A/C, SOD2 Val 16 Ala,SOD3 R213G gene polymorphism may be unrelated to the susceptibility to COPD,but the effect of SOD3 R213G polymorphism on COPD in smokers requires further studies.

参考文献/References:

[1]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,6(4):67-80. [2]刘娅钦,马丽,刘琳.慢性阻塞性肺疾病发病机制的研究进展[J].临床肺科杂志,2016,21(6):1113-1117. [3]兰丰铃,王胜锋,曹卫华,等.慢性阻塞性肺疾病危险因素流行病学研究新进展[J].中华疾病控制杂志,2014,18(10):998-1002. [4]胡大鹏,鲍文华,孙云晖,等.慢性阻塞性肺疾病易感基因研究进展[J].中国老年保健医学,2016,14(6):3-6. [5]Singh S,Verma SK,Kumar S,et al.Evaluation of Oxidative Stress and Antioxidant Status in Chronic Obstructive Pulmonary Disease[J].Scand J Immunol,2017,85(2):130-137. [6]张笑天,郑晓瑛.氧化自由基清除剂超氧化物歧化酶与疾病[J].中国公共卫生,2014,30(10):1349-1352. [7]Kobylecki CJ,Afzal S,Nordestgaard BG.Does SOD3 R213G Homozygosity Influence Morbidity,Mortality,and Lung Function in the General Population[J].Antioxidants&Redox Signaling,2016,24(15):884-891. [8]Young RP,Hopkins R,Black PN,et al.Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function[J].Thorax,2006,61(5):394. [9]Juul K,Tybjaerg-Hansen A,Marklund S,et al.Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2006,173(8):858-864. [10]Korytina GF,Akhmadishina LZ,Cilousova OS,et al.Polymorphism of the genes for antioxidant defense enzymes and their association with the development of chronic obstructive pulmonary disease in the population of Bashkortostan[J].Genetika,2009,45(7):967. [11]Mak JC,Ho SP,Yu WC,et al.Polymorphisms and functional activity in superoxide dismutase and catalase genes in smokers with COPD[J].European Respiratory Journal,2007,30(4):684. [12]Siedlinski M,van Diemen CC,Postma DS,et al.Superoxide dismutases,lung function and bronchial responsiveness in a general population[J].European Respiratory Journal,2009,33(5):986. [13]Houben JM,Mercken EM,Ketelslegers HB,et al.Telomere shortening in chronic obstructive pulmonary disease.[J].Respiratory Medicine,2009,103(2):230-236. [14]Pietras T,Szemraj J,Witusik A,et al.The sequence polymorphism of MnSOD gene in subjects with respiratory insufficiency in COPD[J].Medical Science Monitor International Medical Journal of Experimental&Clinical Research,2010,6(9):CR427. [15]韩轶群,薛玉文,李传芬,等.超氧化物岐化酶基因多态性与慢性阻塞性肺疾病易感性的关系[J].山东大学学报(医学版),2007(09):940-943. [16]魏明霞,董坚,戴路明,等.细胞外超氧化物歧化酶肝素结合区基因多态性与慢性阻塞性肺疾病的关系[J].中华结核和呼吸杂志,2005(12):861-862. [17]夏大庆,徐晓玲,夏淮玲,等.超氧化物歧化酶基因多态性与慢性阻塞性肺疾病的关系[J]. 中国慢性病预防与控制,2013(04):395-398. [18]Kang SW.Superoxide dismutase 2 gene and cancer risk:evidence from an updated meta-analysis[J].Int J ClinExp Med,2015,8(9):14647-14655. [19]Laukkanen MO.Extracellular Superoxide Dismutase:Growth Promoter or Tumor Suppressor[J].Oxidative Medicine and Cellular Longevity,2016,2016(22):1-9. [20]Constantino L,Goncalves RC,Giombelli VR,et al.Regulation of lung oxidative damage by endogenous superoxide dismutase in sepsis[J].Intensive Care Med,2014,2(1):17. [21]周倩倩,徐晓玲,夏大庆.戒烟对慢性阻塞性肺疾病肺功能的影响及机制探讨[J].安徽医科大学学报, 2014(09):1317-1320. [22]林传钦,翟秀丽,邓托.中国人群慢性阻塞肺病相关危险因素的Meta分析[J].实用预防医学,2018(02):191-194. [23]Fischer BM,Voynow JA,Ghio AJ.COPD:balancing oxidants and antioxidants[J].International Journal of Copd,2015,10(1):261-276.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
 ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
 CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
 WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,(17):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
 LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
 LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,(17):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
 ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
 JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,(17):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
 ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
 ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(17):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 2018-09-01